Stifel Nicolaus Cuts Vor Biopharma (NYSE:VOR) Price Target to $5.00

Vor Biopharma (NYSE:VOR) had its target price lowered by Stifel Nicolaus from $12.00 to $5.00 in a research report report published on Friday morning,Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock.

A number of other research firms have also commented on VOR. HC Wainwright reaffirmed a “buy” rating and issued a $17.50 price target on shares of Vor Biopharma in a report on Tuesday, December 10th. Wedbush reissued an “outperform” rating and issued a $7.00 price target on shares of Vor Biopharma in a report on Thursday. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $12.00 price objective on shares of Vor Biopharma in a research note on Tuesday, December 10th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $8.86.

Vor Biopharma Stock Up 2.1 %

NYSE VOR opened at $0.87 on Friday. The company’s 50 day moving average is $1.22 and its 200-day moving average is $1.01. The firm has a market cap of $59.75 million, a P/E ratio of -0.53 and a beta of -0.40. Vor Biopharma has a 12-month low of $0.63 and a 12-month high of $2.43.

Institutional Trading of Vor Biopharma

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Two Sigma Investments LP increased its stake in Vor Biopharma by 18.9% in the fourth quarter. Two Sigma Investments LP now owns 163,064 shares of the company’s stock valued at $181,000 after acquiring an additional 25,930 shares during the last quarter. Trustees of Columbia University in the City of New York bought a new position in shares of Vor Biopharma during the 4th quarter valued at about $102,000. RA Capital Management L.P. raised its holdings in shares of Vor Biopharma by 74.3% during the 4th quarter. RA Capital Management L.P. now owns 39,646,039 shares of the company’s stock valued at $44,007,000 after buying an additional 16,897,159 shares in the last quarter. Northern Trust Corp boosted its stake in Vor Biopharma by 39.0% in the fourth quarter. Northern Trust Corp now owns 157,617 shares of the company’s stock worth $175,000 after buying an additional 44,252 shares in the last quarter. Finally, Lynx1 Capital Management LP bought a new position in Vor Biopharma during the fourth quarter valued at approximately $707,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.